Chao Xu1,2, Xiaoli Xie1, Ning Kang1, Huiqing Jiang3. 1. Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215 Heping Road, Shiijazhuang, 050000, China. 2. Department of Gastroenterology, Handan Central Hospital, Handan, China. 3. Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215 Heping Road, Shiijazhuang, 050000, China. jianghq@aliyun.com.
Abstract
PURPOSE: Programmed cell death protein 1 (PD-1) inhibitor and apatinib have been utilized in metastatic gastric cancer patients. The current study aimed to further investigate the efficacy and safety of neoadjuvant S-1 plus oxaliplatin combined with PD-1 inhibitor and apatinib (SOXPA) in locally advanced gastric cancer (LAGC) patients. METHODS: This two-centered, prospective, cohort study analyzed 30 resectable LAGC patients receiving SOXPA as neoadjuvant therapy. RESULTS: Two (6.7%), 18 (60.0%), and 10 (33.3%) patients achieved complete response (CR), partial response (PR), and stable disease (SD), separately. The objective response rate (ORR) and disease control rate (DCR) were 66.7% and 100.0%, respectively. The R0 resection rate was 93.3%. Beyond that, 6 (20.0%), 18 (60.0%), and 6 (20.0%) patients achieved grade 1, 2, and 3 pathological responses. The pathological complete response (pCR) rate was 20%. The 1-year and 2-year disease-free survival (DFS) rates were 96.6% and 77.7% respectively; meanwhile, the 1-year and 2-year overall survival (OS) rates were 96.6% and 90.1%, separately. What's more, better clinical response (P = 0.046); achievement of ORR (P = 0.014), and better pathological response (P = 0.020) were correlated with longer DFS. Besides, ORR achievement was linked with longer OS (P = 0.040). Most adverse events were relatively mild and manageable. Grade 3 adverse events included leukopenia, anemia, neutropenia, fatigue, hand-foot syndrome, nausea and vomiting. No grade 4 adverse events were witnessed. CONCLUSION: SOXPA as neoadjuvant therapy achieves a satisfying clinical response, pathological response, survival profile, and tolerable safety in LAGC patients.
PURPOSE: Programmed cell death protein 1 (PD-1) inhibitor and apatinib have been utilized in metastatic gastric cancer patients. The current study aimed to further investigate the efficacy and safety of neoadjuvant S-1 plus oxaliplatin combined with PD-1 inhibitor and apatinib (SOXPA) in locally advanced gastric cancer (LAGC) patients. METHODS: This two-centered, prospective, cohort study analyzed 30 resectable LAGC patients receiving SOXPA as neoadjuvant therapy. RESULTS: Two (6.7%), 18 (60.0%), and 10 (33.3%) patients achieved complete response (CR), partial response (PR), and stable disease (SD), separately. The objective response rate (ORR) and disease control rate (DCR) were 66.7% and 100.0%, respectively. The R0 resection rate was 93.3%. Beyond that, 6 (20.0%), 18 (60.0%), and 6 (20.0%) patients achieved grade 1, 2, and 3 pathological responses. The pathological complete response (pCR) rate was 20%. The 1-year and 2-year disease-free survival (DFS) rates were 96.6% and 77.7% respectively; meanwhile, the 1-year and 2-year overall survival (OS) rates were 96.6% and 90.1%, separately. What's more, better clinical response (P = 0.046); achievement of ORR (P = 0.014), and better pathological response (P = 0.020) were correlated with longer DFS. Besides, ORR achievement was linked with longer OS (P = 0.040). Most adverse events were relatively mild and manageable. Grade 3 adverse events included leukopenia, anemia, neutropenia, fatigue, hand-foot syndrome, nausea and vomiting. No grade 4 adverse events were witnessed. CONCLUSION: SOXPA as neoadjuvant therapy achieves a satisfying clinical response, pathological response, survival profile, and tolerable safety in LAGC patients.
Authors: Haejin In; Ethan Ravetch; Marisa Langdon-Embry; Bryan Palis; Jaffer A Ajani; Wayne L Hofstetter; David P Kelsen; Takeshi Sano Journal: Gastric Cancer Date: 2017-09-25 Impact factor: 7.370
Authors: Jaffer A Ajani; Thomas A D'Amico; David J Bentrem; Joseph Chao; David Cooke; Carlos Corvera; Prajnan Das; Peter C Enzinger; Thomas Enzler; Paul Fanta; Farhood Farjah; Hans Gerdes; Michael K Gibson; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Rajesh N Keswani; Sunnie Kim; Lawrence R Kleinberg; Samuel J Klempner; Jill Lacy; Quan P Ly; Kristina A Matkowskyj; Michael McNamara; Mary F Mulcahy; Darryl Outlaw; Haeseong Park; Kyle A Perry; Jose Pimiento; George A Poultsides; Scott Reznik; Robert E Roses; Vivian E Strong; Stacey Su; Hanlin L Wang; Georgia Wiesner; Christopher G Willett; Danny Yakoub; Harry Yoon; Nicole McMillian; Lenora A Pluchino Journal: J Natl Compr Canc Netw Date: 2022-02 Impact factor: 11.908
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Yoon-Koo Kang; Jeong Hwan Yook; Young-Kyu Park; Jong Seok Lee; Young-Woo Kim; Jin Young Kim; Min-Hee Ryu; Sun Young Rha; Ik Joo Chung; In-Ho Kim; Sang Cheul Oh; Young Soo Park; Taeil Son; Mi Ran Jung; Mi Hwa Heo; Hark Kyun Kim; ChoHyun Park; Chang Hak Yoo; Jin-Hyuk Choi; Dae Young Zang; You Jin Jang; Ji Young Sul; Jong Gwang Kim; Beom Su Kim; Seung-Hoon Beom; Sang Hee Cho; Seung Wan Ryu; Myeong-Cherl Kook; Baek-Yeol Ryoo; Hyun Ki Kim; Moon-Won Yoo; Nam Su Lee; Sang Ho Lee; Gyunji Kim; YeonJu Lee; Jee Hyun Lee; Sung Hoon Noh Journal: J Clin Oncol Date: 2021-06-16 Impact factor: 50.717